Highlights Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 06/05/2024 BST			5-day change	1st Jan Change
47.23 ^CNY	+0.15%		+2.32%	+4.42%

04-26	Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	MT
04-17	Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%	04-26	MT
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-17	CI
Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-17	CI
Hengrui Pharma's Units Get Nod to Trial Four Cancer Drugs	04-11	MT
Hengrui Pharma's Units Get Approval to Trial Two Gastric Cancer Drugs	04-09	MT
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	04-01	CI
Hengrui Pharma Gets Nod for Injectable Cancer Drug Trial	03-27	MT
Hengrui Pharma Gets Green Light to Trial Four Cancer Drugs	03-19	MT
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE
Hengrui Pharma Gets Green Light to Trial Tumor Drug Combination	03-01	MT
Hengrui Pharma Gets China Nod to Trial Combo Treatment for Breast Cancer	02-28	MT
Hengrui Pharma's Unit Gets Nod to Trial Adebelimab Injection	02-23	MT
GSK completes acquisition of Aiolos Bio for up to $1.4 bln	02-15	RE
Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s Commercial Launch of Vivjoa (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China	02-07	CI
Cancer Drug of Hengrui Pharmaceuticals' Unit Placed in China's List of Breakthrough Therapy Drugs; Shares Climb 4%	02-05	MT
Hengrui Pharmaceuticals Gets Nod for Taglidine Fumarate Injection	02-01	MT
Hengrui Pharma's Unit Gets Nod to Trial Adbelimab Injection	01-17	MT
Hengrui Pharmaceuticals, Subsidiary Get Chinese Drug Regulator's Nod for Two Drugs	01-08	MT
China money managers rush to create funds tracking new A50 index	01-03	RE
Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.	01-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jiangsu Hengrui Medicine Co., Ltd.

Equities

600276

CNE0000014W7

Highlights

Filters